NAT2
NAT2 (N-acetyltransferase 2, also known as arylamine N-acetyltransferase 2 or AAC2) is a cytoplasmic enzyme that catalyses the N- or O-acetylation of arylamine and heterocyclic amine substrates. It contributes to the metabolism of drugs and carcinogens, and underlies the human acetylator polymorphism. Browse Assay Genie's current range of NAT2 research reagents below, or read on for the biology behind the target.
NAT2 catalyses the N- or O-acetylation of a wide range of arylamine and heterocyclic amine substrates. In this role it participates in the detoxification of many hydrazine and arylamine drugs. The same activity can also bioactivate several known carcinogens, so the enzyme both activates and deactivates arylamine and hydrazine compounds depending on the substrate. This dual character is why NAT2 is a recurring subject in pharmacology and toxicology.
The NAT2 gene encodes arylamine N-acetyltransferase 2, a cytoplasmic member of the arylamine N-acetyltransferase family, which is also the HGNC gene group for this protein. Polymorphisms in the gene are responsible for the N-acetylation polymorphism, in which human populations segregate into rapid, intermediate and slow acetylator phenotypes. These variants are also associated with higher incidences of cancer and drug toxicity, which makes the NAT2 gene a standard example in pharmacogenetics. A rat ortholog, Nat2, is listed for comparative work.
A second polymorphic arylamine N-acetyltransferase gene, NAT1, lies close to NAT2 in the genome, and the two enzymes are often studied together when examining acetylation of xenobiotics. The gene was formerly named N-acetyltransferase 2 (arylamine N-acetyltransferase), and AAC2 appears as an alias in older literature. Researchers studying NAT2 commonly use an NAT2 antibody, NAT2 ELISA kit or recombinant NAT2 protein to examine expression, activity and the biochemical effects of acetylator variants in models of drug metabolism and chemical carcinogenesis.
Polymorphisms in NAT2 define rapid, intermediate and slow acetylator phenotypes, making it a central gene for studying inter-individual differences in drug handling.
NAT2 participates in the detoxification of many hydrazine and arylamine drugs through N- or O-acetylation of the parent compounds.
NAT2 variants are associated with a higher incidence of drug toxicity, so the enzyme is relevant to adverse-reaction studies.
NAT2 can bioactivate several known carcinogens, and its polymorphisms are associated with higher incidences of cancer.
NAT2 catalyses the N- or O-acetylation of various arylamine and heterocyclic amine substrates. It helps detoxify many hydrazine and arylamine drugs, but it can also bioactivate several known carcinogens. It is therefore described as both activating and deactivating these compounds.
The HGNC name is N-acetyltransferase 2, and UniProt lists the protein as arylamine N-acetyltransferase 2. AAC2 is a recorded alias. The previous HGNC name was N-acetyltransferase 2 (arylamine N-acetyltransferase). The enzyme carries the EC number 2.3.1.5.
Polymorphisms in the NAT2 gene are responsible for the N-acetylation polymorphism, in which people segregate into rapid, intermediate and slow acetylators. These variants are also associated with higher incidences of cancer and drug toxicity. A rat ortholog, Nat2, is listed; check the datasheet of any product for its validated reactivity.
NAT1, other N-acetyltransferases and related xenobiotic-metabolism targets with products at Assay Genie.
Gene and protein annotations from HGNC, NCBI Gene and UniProt P11245; product specifications from Assay Genie datasheets.